ABG
URGN icon

Ally Bridge Group’s UroGen Pharma URGN Stock Holding History

Ally Bridge Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.55M Sell
69,183
-132,941
-66% -$3.6M 2.25% 17
2026
Q1 		$3.63M Buy
+202,124
New +$4.05M 2.94% 19

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ally Bridge Group's URGN Position: Q2 2026 in Review

Ally Bridge Group reduced its UroGen Pharma (URGN) stake by 66% in Q2 2026, selling an estimated $3.6M and leaving 69,183 shares worth $2.55M. The position accounts for 2.25% of the portfolio, ranked #17.

Ally Bridge Group first reported a position in URGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.63M in Q1 2026. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Ally Bridge Group held 69,183 shares of UroGen Pharma worth $2.55M as of Q2 2026.
  • Ally Bridge Group sold 132,941 UroGen Pharma shares in Q2 2026, an estimated $3.6M.
  • UroGen Pharma made up 2.25% of Ally Bridge Group's portfolio in Q2 2026, its #17 holding.
  • Ally Bridge Group first reported a position in UroGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Ally Bridge Group's UroGen Pharma position peaked at $3.63M in Q1 2026.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.